Influence of antigen density and TLR ligands on preclinical efficacy of a VLP-based vaccine against peanut allergy.
Pascal S KrengerRomano JosiJan SobczakThalia L C VelazquezIna BalkeMurray A SkinnerMatthias F KramerCallum J W ScottSimon HewingsMatthew D HeathAndris ZeltinsMartin F BachmannPublished in: Allergy (2023)
Our findings demonstrate that prokaryotic RNA encapsulated within VLP Peanut, including antigen density of Ara h 2 on viral particles, are key contributors to the immunogenicity and protective capacity of the vaccine. Thus, antigenicity and RNA content are two critical quality attributes that need to be determined at the stage of manufacturing, providing robust information regarding the immunogenicity and protective capacity of VLP Peanut in the mouse which has translational relevance to the human setting.